Bestselling Author Announces He is Using Tumor Suppressant Gene Booster to Treat His Kidney Cancer

Adult Book Recomendations

West Palm Beach, FL, February 23, 2023 — Steve Alten, author of 18 thrillers, including the bestselling MEG series, and founder of the nonprofit Adopt-an-Author teen reading program, recently announced that a tumor discovered on his right kidney is malignant. Given a choice of surgery followed by chemotherapy, Alten opted for a little-known cancer treatment that he says he has been trying to bring to the medical field’s attention ever since the scientist who created it died 18 months ago.

“It’s called GC-6000, and it’s the brainchild of the late Dr. John Grinstein, an Israeli-trained biochemist who simplified treating and reversing all cancers down to a far easier problem to solve,” Alten explained.

Dr. Grinstein studied the body’s own tumor suppressant gene, called p53, which has the ability to force a malignant cell to self-destruct (apoptosis) and facilitates the repair of damaged DNA. Aging and oxidative stress are two factors that can weaken the p53 gene.

“Dr. Grinstein’s expertise was in knowing how to use the disease-fighting properties found in certain fruits and vegetables to help rejuvenate the p53 gene,” Alten added.

According to Dr. Grinstein’s records, his formulas have successfully treated and reversed the worst stage 4 cancers, including multicentric glioblastoma as well as other forms of brain cancer.

“Dr. G’s protocol saved two of my friends’ lives — one diagnosed with stage 4 pancreatic cancer who was given three months to live,” Alten said. “The GC works fast. In 4-5 weeks, my friend’s tumor had shrunk in half, and in nine months his oncologist declared him to be cancer-free. His testimonial and dozens more are available to watch at www.GoneCancer.com.”

Before he passed away, Dr. Grinstein taught his assistants how to produce his cancer fighting formulas, including his GC-6000, which Alten is using to combat his kidney cancer.

Alten’s treatment with GC-6000 is being overseen by his own team of physicians. All information about the protocol, along with videos, patient testimonials and updates on Alten’s progress is made public on the website www.GoneCancer.com. After March 3, visitors to the site can find the results of Alten’s 90-day CT scan to show whether or not the treatment has had any effect on his tumor.

Alten chose to share his deeply personal journey to encourage progress in all areas of cancer research and treatment — particularly in regard to all-natural therapies.

Thank you,

Glenda, Charlie and David Cates